Sign Out
Antihypertensive agents (e.g., ACE-inhibitors, β-blockers, vasodilators): Meloxicam and other NSAIDs may reduce the effect of antihypertensive agents through inhibition of vasodilatory prostaglandins.
Bile acid sequestrants (e.g., cholestyramine): Concomitant administration of bile acid sequestrants and meloxicam may increase the clearance of Meloxicam by 50%.
Aspirin and Other NSAIDs: Concomitant administration of Meloxicam with low-dose aspirin or other NSAIDs may result in increased rate of GI ulceration or other complications.
Ciclosporin: The effects of NSAIDs on renal prostaglandins may increase the nephrotoxicity of Ciclosporin.
Diuretics: As with other NSAIDs, Meloxicam can reduce the natriuretic effect of furosemide and thiazides in some patients due to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, observe patients closely for signs of renal failure, as well as to assure diuretic efficacy.
Lithium: NSAIDs, including Meloxicam, have produced significant elevation of plasma Lithium levels. This effect is attributed to Meloxicam's inhibition of renal prostaglandin synthesis. Closely monitor patients for signs of Lithium toxicity when NSAIDs and Lithium are administered concurrently.
Methotrexate: NSAIDs could enhance the toxicity of Methotrexate. Use caution when NSAIDs are administered concomitantly with methotrexate.
Oral anticoagulants (e.g., Warfarin), antiplatelet drugs, thrombolytics, and systemically administered Heparin: NSAIDs increase the risk of bleeding when co-administered with these agents.
Cimetidine, Digoxin: Pharmacokinetic interaction with Meloxicam is unlikely.
